EphB4/ephrinB2逆向信号抑制RANKL诱导的Raw264.7破骨细胞分化的机制研究
|
摘要
破骨细胞的骨吸收活动与成骨细胞的骨形成活动相互作用调节,形成一种特殊的耦联机制,维持骨平衡。该耦联机制调节发生异常,会破坏骨重建和骨稳态,引发骨硬化症、骨质疏松症等骨量平衡失调所致的疾病以及肿瘤、炎症等所致的骨质异常表型。因此,该耦联的分子机制一直是骨生理和骨疾病研究、治疗及药物研发的重点对象。近几十年,关于该耦联的分子机制研究最多的就是早期提出的RANKL/RANK信号系统,即成骨细胞及骨髓基质细胞释放的RANKL,与破骨前体细胞膜表面的受体RANK结合,促进破骨前体细胞分化融合为成熟的破骨细胞。而近几年,Eph/ephrin信号转导通路异军突起,凭借对成骨细胞、破骨细胞耦联活动中关键问题的成功诠释,在骨组织领域受到越来越多的关注。
骨组织中,EphB4/ephrinB2双向信号转导同时促进成骨细胞分化,而抑制破骨细胞分化。这是膜蛋白Eph受体与其配体ephrin相互作用的一个重要特征,即ephrin配体兼具受体样的功能,同时产生双向信号转导。其中,向Eph表达细胞胞内转导信号,称之为正向信号；反向ephrin自身表达细胞胞内转导信号,称之为逆向信号。EphB4/ephrinB2逆向信号对破骨细胞诱导分化的抑制作用依赖于ephrinB配体胞内区的C末端YKV基序,YKV基序含PDZ结构域蛋白的结合位点,提示有潜在的PDZ结构域蛋白参与到EphB4/ephrinB2逆向信号下游转导途径。这个或这些未知的PDZ结构域蛋白是调节骨重建的重要潜在靶点
本课题研究拟在体外破骨细胞诱导分化过程中,筛选出参与到EphB4/ephrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白种类,并初步探索其表达变化是否受EphB4/ephrinB2逆向信号调控。
第一部分建立EphB4/ephrinB2逆向信号抑制RANKL诱导的Raw264.7破骨细胞分化模型
目的：
考虑到原代细胞培养间存在个体差异性及来源选择的局限性等不利因素,细胞株因其标准的实验试剂培养步骤及结果的可重复性、可复制性等优点越来越多的用于生命科学基础研究中。本课题拟以单核巨噬细胞系细胞Raw264.7细胞株作为潜在的破骨前体细胞,研究EphB4/ephrinB2逆向信号对RANKL诱导的Raw264.7破骨细胞分化行为及关键转录因子(c-Fos, c-Jun, NFATcl)基因表达的影响,分析其是否适合本课题研究需要。
方法：
在RANKL刺激下,诱导Raw264.7细胞分化为破骨样细胞。用免疫荧光细胞化学、荧光实时定量RT-PCR技术及Western blot技术检测分析细胞分化前后是否表达ephrinB2。以加入Fc蛋白为对照,加入EphB4-Fc蛋白到上述培养液中为实验组,诱导培养4天后,用TRAP染色试剂盒分析各组细胞的耐酒石酸盐酸性磷酸酶活性变化,用荧光实时定量RT-PCR技术分析各组细胞破骨细胞分化相关标志酶基因的表达变化,及细胞中RANKL/RANK信号系统下游关键转录因子(c-Fos, c-Jun, NFATcl)基因的表达变化。
结果：
免疫荧光细胞化学、荧光实时定量RT-PCR技术及Western blot检测结果示：经RANKL诱导分化的Raw264.7破骨样细胞有ephrinB2蛋白表达,未经诱导分化的Raw264.7细胞未见ephrinB2蛋白表达。Raw264.7诱导培养液中加入EphB4-Fc蛋白后,TRAP阳性多核破骨细胞数量明显减少(P<0.01),破骨细胞分化相关标志酶基因的表达也明显减少(P<0.01),关键转录因子(c-Fos, c-Jun, NFATc1)基因的表达亦明显下降(P<0.01)。
结论：
EphB4/ephrinB2逆向信号抑制RANKL诱导的Raw264.7破骨细胞分化。Raw264.7细胞可用作研究EphB4/ephrinB2逆向信号的细胞模型,适合本课题研究的需要。
第二部分筛选参与EphB4/cphrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白
目的：
膜蛋白ephrinB2有一个跨膜结构域和很短的胞内区,胞内区域是高度保守的,含有多重酪氨酸,而C末端YKV基序含PDZ结构域蛋白的结合位点。本课题研究拟筛选RANKL诱导的Raw264.7破骨细胞分化过程中参与EphB4/ephrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白。
方法：
免疫荧光细胞化学及Western blot检测分析在RANKL诱导的Raw264.7破骨细胞分化前后PDZ结构域蛋白(PDZ-RGS3, Dv12, Pick1, Syntenin, GRIP1, GRIP2, FAP-1 and Par3)的表达。免疫共沉淀技术分析诱导分化后有表达的PDZ结构域蛋白是否能与ephrinB2共沉淀,从生物化学角度,初步筛选出可能参与EphB4/ephrinB2逆向信号下游信号转导的潜在PDZ结构域蛋白。EphB4-Fc蛋白加入到含RANKL的Raw264.7细胞培养液中,诱导培养4天后,荧光实时定量RT-PCR及Western blot技术比较分析潜在PDZ结构域蛋白的表达变化。
结果：
免疫荧光细胞化学及Western blot检测结果示：Raw264.7经RANKL诱导分化4天后的破骨细胞内8种PDZ结构域蛋白都有明显表达。免疫共沉淀分析结果示：仅有Dvl2蛋白能与ephrinB2共沉淀,其他蛋白未见共沉淀结果。Western blot及荧光实时定量RT-PCR技术分析结果示：在EphB4实验组中Dvl2的蛋白表达明显低于Fc对照组(P＜0.01), mRNA表达亦低于Fc对照组,但不具有统计学差异(P>0.05)。另外,虽然免疫共沉淀实验未显示Pickl和syntenin与ephrinB2结合,但Western blot及荧光实时定量RT-PCR技术分析结果示：在EphB4实验组中Pick1的蛋白表达明显强于Fc对照组(P＜O.01), mRNA表达量亦明显高于Fc对照组(P<0.01);而在EphB4实验组及Fc对照组间syntenin蛋白及mRNA表达量无明显差异(P>0.05)。
结论：
RANKL诱导的Raw264.7破骨细胞分化过程中,Dvl2蛋白是参与EphB4/ephrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白分子。
Osteoclastic bone resorption and osteoblastic bone formation are coordinated as a coupled mechanism to maintain bone homeostasis. This coupling is of great importance because a large majority of the diseases of bone that result in changes in bone mass, such as osteoporosis and osteopetrosis, are due to disruption of the coupling. The molecular mechanisms that are responsible for osteoclast-osteoblast communication remain one of the central issues in bone cell biology. Over the past decades, the pivotal roles of the receptor activator of NF-κB (RANK), its ligand RANKL. and the natural decoy receptor for RANKL, osteoprotegerin (OPG) have been well-documented. The binding of RANKL, which is released by osteoblasts and bone marrow cells, to its receptor RANK has an essential role in the differentiation and fusion of precursors into mature osteoclasts. There is recent evidence to suggest a role for the Eph receptors and their ephrin ligands in bone biology, a role that may affect the coupling between osteoblasts and osteoclasts.
An important characteristic of interactions between Eph receptors and ephrin ligands is the bidirectional signaling, due to activation of signaling pathways in both the receptor-expressing and the ligand-expressing cells. Activation of the EphB receptors by the ephrinB ligands is designated as "forward signaling". Conversely, activation of the ephrinB ligands by the EphB receptors is referred to "reverse signaling". The reverse inhibitory effect in osteoclasts is dependent on the cytoplasmic domain of ephrinB2, while the C-terminal YKV motif is critical for signal transduction, indicating that downstream PDZ-domain proteins are involved.
This pilot_study was designed to preliminarily identify the potential PDZ-domain proteins involved downstream of ephrinB2 during the osteoclast differentiation of Raw264.7 cells in vitro, and to find out whether the expression levels of potential PDZ-domain proteins are regulated by EphB4/ephrinB2 reverse signaling.
Part I Establishing the osteoclastogenesis model that EphB4/ephrinB2 reverse signaling inhibits RANKL-induced osteoclast differentiation of Raw264.7 cells
Purpose:
The first step of our study was to select the type of osteoclastic precursors to be used for further research. However, inter-individual variability and insufficient material are disadvantages of working with primary cell cultures, and cell lines are being increasingly recognized as standard experimental reagents and as essential components to ensure reproducible and reliable results in life science research. Our study used Raw264.7 cells, a macrophage/monocyte lineage cell line, as osteoclast precursors, and to examine the effect of EphB4/ephrinB2 reverse signaling on the RANKL-induced osteoclastogenesis and the gene expression of critical transcriptional factors such as c-Fos. c-Jun and NFATc 1.
Methods:
Raw264.7 was used in this study and could be differentiated into osteoclast-like cells on activation by RANKL. The detection of ephrinB2 protein was examined by immunofluorescence techniques and the western blot. The EphB4 protein was added to nutrient solution to find out the effect of EphB4/ephrinB2 reverse signaling on the osteoclast differentiation of Raw264.7 cells. After 4 days, the cultured cells were stained by a leukocyte acid phosphatase kit to analyze the cytochemical tartrate-resistant acid phosphatase (TRAP). The Expression of the marker enzyme gene of osteoclast differentiation of Raw264.7 cells, and transcriptional factors such as c-Fos, c-Jun and NFATc1, were assessed by quantitative real-time RT-PCR.
Results:
By immunofluorescence techniques and the western blot, the expression of ephrinB2 protein was detected in the RANKL induced osteoclast differentiation of Raw264.7 cells, but was not detected in the absence of RANKL. After four days in the conditioning culture, TRAP staining was performed, and TRAP-positive MNCs in each well were counted as osteoclasts. The number of TRAP-positive MNCs was significantly lower in the EphB4-Fc treated group than that in the Fc treated group (P<0.01). Total RNA was collected and analyzed, and the results showed that the EphB4-Fc treatment reduced the mRNA expression levels of osteoclast specific genes such as TRAP, cathepsin K and calcitonin receptor compared with the Fc treatment (P0.01). The mRNA level of these transcription factors was also reduced in the EphB4-Fc treated group compared with the Fc treated group (P<0.01).
Conclusions:
These results show that EphB4/ephrinB2 reverse signaling inhibits RANKL-induced osteoclast differentiation of Raw264.7 cells.
PartⅡA preliminary identification of potential PDZ-domain proteins downstream of ephrinB2 during osteoclast differentiation of Raw264.7 cells
Purpose:
The intracellular domain of ephrinB ligands, particularly the last 33 C-terminal amino acids, is highly conserved and contains multiple tyrosine residues, and the C-terminal YKV motif is a binding site for PDZ (postsynaptic density protein, disks large, zona occludens) domain-containing proteins. This pilot study was designed to preliminarily identify the potential PDZ-domain proteins involved downstream of ephrinB2 during the osteoclast differentiation of Raw264.7 cells in vitro.
Methods:
The immunofluorescence staining and western blot analysis were used to identify potential PDZ-domain proteins (PDZ-RGS3. Dv12, Pickl/PHIP, Syntenin, GRIP1, GRIP2, FAP-1 and Par3) expressed during the RANKL-induced osteoclast differentiation of Raw264.7 cells. To investigate whether ephrinB2 ligands associate with any of these potential PDZ-domain proteins, we immunoprecipitated ephrinB2 proteins from the cell lysis buffer with a goat polyclonal antibody, and the precipitate was assayed for coimmunoprecipitated PDZ-domain proteins by immunoblotting. Finally, to find out whether the EphB4-ephrinB2 reverse signaling affects the expression level of potential PDZ-domain proteins, preclustered soluble EphB4-Fc or Fc fragments were added to the RANKL-induced osteoclastogenic cultures. After four days in the conditioning culture, the expressions of the potential PDZ-domain proteins were assessed by the western blot and quantitative real-time RT-PCR.
Results:
The immunofluorescence staining and western blot analysis revealed that the eight PDZ-domain proteins were all expressed in the RANKL+ group after four days in the conditioning culture. However, among the eight proteins, only Dv12 showed the expected size coprecipitated with ephrinB2, and the reverse experiment (immunoprecipitation by the Dv12 antibody and immunoblotting by the ephrinB2 antibody) confirmed the relationship. The other PDZ-domain proteins were not detected at the expected sizes in the precipitate after immunoprecipitation with the ephrinB2 antibody in three independent experiments. After four days in the conditioning culture, the western blot showed that the band for Dv12 in the EphB4-Fc treated group was weaker than that in the Fc treated group (P<0.01), and the mRNA level of Dvl2 in the EphB4-Fc treated group was a little lower than in the Fc treated group, albeit with no statistical significance (P>0.05). What is more, we studied the effects of reverse signaling on the expression levels of Pickl and syntenin, PDZ-domain proteins which could not coprecipitate with ephrinB2. The western blot and quantitative real-time RT-PCR results showed that, in contrast to the similar expression level of syntenin between EphB4-Fc treated group and Fc treated group (P>0.05), the protein and mRNA expression levels of Pickl were obviously enhanced in EphB4-Fc treated group compared with Fc treated group (P<0.01).
Conclusions:
Dv12 may be the potential downstream PDZ-domain protein that is the binding partner for the C-terminal YKV motif of ephrinB2.
骨组织中,EphB4/ephrinB2双向信号转导同时促进成骨细胞分化,而抑制破骨细胞分化。这是膜蛋白Eph受体与其配体ephrin相互作用的一个重要特征,即ephrin配体兼具受体样的功能,同时产生双向信号转导。其中,向Eph表达细胞胞内转导信号,称之为正向信号；反向ephrin自身表达细胞胞内转导信号,称之为逆向信号。EphB4/ephrinB2逆向信号对破骨细胞诱导分化的抑制作用依赖于ephrinB配体胞内区的C末端YKV基序,YKV基序含PDZ结构域蛋白的结合位点,提示有潜在的PDZ结构域蛋白参与到EphB4/ephrinB2逆向信号下游转导途径。这个或这些未知的PDZ结构域蛋白是调节骨重建的重要潜在靶点
本课题研究拟在体外破骨细胞诱导分化过程中,筛选出参与到EphB4/ephrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白种类,并初步探索其表达变化是否受EphB4/ephrinB2逆向信号调控。
第一部分建立EphB4/ephrinB2逆向信号抑制RANKL诱导的Raw264.7破骨细胞分化模型
目的：
考虑到原代细胞培养间存在个体差异性及来源选择的局限性等不利因素,细胞株因其标准的实验试剂培养步骤及结果的可重复性、可复制性等优点越来越多的用于生命科学基础研究中。本课题拟以单核巨噬细胞系细胞Raw264.7细胞株作为潜在的破骨前体细胞,研究EphB4/ephrinB2逆向信号对RANKL诱导的Raw264.7破骨细胞分化行为及关键转录因子(c-Fos, c-Jun, NFATcl)基因表达的影响,分析其是否适合本课题研究需要。
方法：
在RANKL刺激下,诱导Raw264.7细胞分化为破骨样细胞。用免疫荧光细胞化学、荧光实时定量RT-PCR技术及Western blot技术检测分析细胞分化前后是否表达ephrinB2。以加入Fc蛋白为对照,加入EphB4-Fc蛋白到上述培养液中为实验组,诱导培养4天后,用TRAP染色试剂盒分析各组细胞的耐酒石酸盐酸性磷酸酶活性变化,用荧光实时定量RT-PCR技术分析各组细胞破骨细胞分化相关标志酶基因的表达变化,及细胞中RANKL/RANK信号系统下游关键转录因子(c-Fos, c-Jun, NFATcl)基因的表达变化。
结果：
免疫荧光细胞化学、荧光实时定量RT-PCR技术及Western blot检测结果示：经RANKL诱导分化的Raw264.7破骨样细胞有ephrinB2蛋白表达,未经诱导分化的Raw264.7细胞未见ephrinB2蛋白表达。Raw264.7诱导培养液中加入EphB4-Fc蛋白后,TRAP阳性多核破骨细胞数量明显减少(P<0.01),破骨细胞分化相关标志酶基因的表达也明显减少(P<0.01),关键转录因子(c-Fos, c-Jun, NFATc1)基因的表达亦明显下降(P<0.01)。
结论：
EphB4/ephrinB2逆向信号抑制RANKL诱导的Raw264.7破骨细胞分化。Raw264.7细胞可用作研究EphB4/ephrinB2逆向信号的细胞模型,适合本课题研究的需要。
第二部分筛选参与EphB4/cphrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白
目的：
膜蛋白ephrinB2有一个跨膜结构域和很短的胞内区,胞内区域是高度保守的,含有多重酪氨酸,而C末端YKV基序含PDZ结构域蛋白的结合位点。本课题研究拟筛选RANKL诱导的Raw264.7破骨细胞分化过程中参与EphB4/ephrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白。
方法：
免疫荧光细胞化学及Western blot检测分析在RANKL诱导的Raw264.7破骨细胞分化前后PDZ结构域蛋白(PDZ-RGS3, Dv12, Pick1, Syntenin, GRIP1, GRIP2, FAP-1 and Par3)的表达。免疫共沉淀技术分析诱导分化后有表达的PDZ结构域蛋白是否能与ephrinB2共沉淀,从生物化学角度,初步筛选出可能参与EphB4/ephrinB2逆向信号下游信号转导的潜在PDZ结构域蛋白。EphB4-Fc蛋白加入到含RANKL的Raw264.7细胞培养液中,诱导培养4天后,荧光实时定量RT-PCR及Western blot技术比较分析潜在PDZ结构域蛋白的表达变化。
结果：
免疫荧光细胞化学及Western blot检测结果示：Raw264.7经RANKL诱导分化4天后的破骨细胞内8种PDZ结构域蛋白都有明显表达。免疫共沉淀分析结果示：仅有Dvl2蛋白能与ephrinB2共沉淀,其他蛋白未见共沉淀结果。Western blot及荧光实时定量RT-PCR技术分析结果示：在EphB4实验组中Dvl2的蛋白表达明显低于Fc对照组(P＜0.01), mRNA表达亦低于Fc对照组,但不具有统计学差异(P>0.05)。另外,虽然免疫共沉淀实验未显示Pickl和syntenin与ephrinB2结合,但Western blot及荧光实时定量RT-PCR技术分析结果示：在EphB4实验组中Pick1的蛋白表达明显强于Fc对照组(P＜O.01), mRNA表达量亦明显高于Fc对照组(P<0.01);而在EphB4实验组及Fc对照组间syntenin蛋白及mRNA表达量无明显差异(P>0.05)。
结论：
RANKL诱导的Raw264.7破骨细胞分化过程中,Dvl2蛋白是参与EphB4/ephrinB2逆向信号下游信号转导途径的潜在PDZ结构域蛋白分子。
Osteoclastic bone resorption and osteoblastic bone formation are coordinated as a coupled mechanism to maintain bone homeostasis. This coupling is of great importance because a large majority of the diseases of bone that result in changes in bone mass, such as osteoporosis and osteopetrosis, are due to disruption of the coupling. The molecular mechanisms that are responsible for osteoclast-osteoblast communication remain one of the central issues in bone cell biology. Over the past decades, the pivotal roles of the receptor activator of NF-κB (RANK), its ligand RANKL. and the natural decoy receptor for RANKL, osteoprotegerin (OPG) have been well-documented. The binding of RANKL, which is released by osteoblasts and bone marrow cells, to its receptor RANK has an essential role in the differentiation and fusion of precursors into mature osteoclasts. There is recent evidence to suggest a role for the Eph receptors and their ephrin ligands in bone biology, a role that may affect the coupling between osteoblasts and osteoclasts.
An important characteristic of interactions between Eph receptors and ephrin ligands is the bidirectional signaling, due to activation of signaling pathways in both the receptor-expressing and the ligand-expressing cells. Activation of the EphB receptors by the ephrinB ligands is designated as "forward signaling". Conversely, activation of the ephrinB ligands by the EphB receptors is referred to "reverse signaling". The reverse inhibitory effect in osteoclasts is dependent on the cytoplasmic domain of ephrinB2, while the C-terminal YKV motif is critical for signal transduction, indicating that downstream PDZ-domain proteins are involved.
This pilot_study was designed to preliminarily identify the potential PDZ-domain proteins involved downstream of ephrinB2 during the osteoclast differentiation of Raw264.7 cells in vitro, and to find out whether the expression levels of potential PDZ-domain proteins are regulated by EphB4/ephrinB2 reverse signaling.
Part I Establishing the osteoclastogenesis model that EphB4/ephrinB2 reverse signaling inhibits RANKL-induced osteoclast differentiation of Raw264.7 cells
Purpose:
The first step of our study was to select the type of osteoclastic precursors to be used for further research. However, inter-individual variability and insufficient material are disadvantages of working with primary cell cultures, and cell lines are being increasingly recognized as standard experimental reagents and as essential components to ensure reproducible and reliable results in life science research. Our study used Raw264.7 cells, a macrophage/monocyte lineage cell line, as osteoclast precursors, and to examine the effect of EphB4/ephrinB2 reverse signaling on the RANKL-induced osteoclastogenesis and the gene expression of critical transcriptional factors such as c-Fos. c-Jun and NFATc 1.
Methods:
Raw264.7 was used in this study and could be differentiated into osteoclast-like cells on activation by RANKL. The detection of ephrinB2 protein was examined by immunofluorescence techniques and the western blot. The EphB4 protein was added to nutrient solution to find out the effect of EphB4/ephrinB2 reverse signaling on the osteoclast differentiation of Raw264.7 cells. After 4 days, the cultured cells were stained by a leukocyte acid phosphatase kit to analyze the cytochemical tartrate-resistant acid phosphatase (TRAP). The Expression of the marker enzyme gene of osteoclast differentiation of Raw264.7 cells, and transcriptional factors such as c-Fos, c-Jun and NFATc1, were assessed by quantitative real-time RT-PCR.
Results:
By immunofluorescence techniques and the western blot, the expression of ephrinB2 protein was detected in the RANKL induced osteoclast differentiation of Raw264.7 cells, but was not detected in the absence of RANKL. After four days in the conditioning culture, TRAP staining was performed, and TRAP-positive MNCs in each well were counted as osteoclasts. The number of TRAP-positive MNCs was significantly lower in the EphB4-Fc treated group than that in the Fc treated group (P<0.01). Total RNA was collected and analyzed, and the results showed that the EphB4-Fc treatment reduced the mRNA expression levels of osteoclast specific genes such as TRAP, cathepsin K and calcitonin receptor compared with the Fc treatment (P0.01). The mRNA level of these transcription factors was also reduced in the EphB4-Fc treated group compared with the Fc treated group (P<0.01).
Conclusions:
These results show that EphB4/ephrinB2 reverse signaling inhibits RANKL-induced osteoclast differentiation of Raw264.7 cells.
PartⅡA preliminary identification of potential PDZ-domain proteins downstream of ephrinB2 during osteoclast differentiation of Raw264.7 cells
Purpose:
The intracellular domain of ephrinB ligands, particularly the last 33 C-terminal amino acids, is highly conserved and contains multiple tyrosine residues, and the C-terminal YKV motif is a binding site for PDZ (postsynaptic density protein, disks large, zona occludens) domain-containing proteins. This pilot study was designed to preliminarily identify the potential PDZ-domain proteins involved downstream of ephrinB2 during the osteoclast differentiation of Raw264.7 cells in vitro.
Methods:
The immunofluorescence staining and western blot analysis were used to identify potential PDZ-domain proteins (PDZ-RGS3. Dv12, Pickl/PHIP, Syntenin, GRIP1, GRIP2, FAP-1 and Par3) expressed during the RANKL-induced osteoclast differentiation of Raw264.7 cells. To investigate whether ephrinB2 ligands associate with any of these potential PDZ-domain proteins, we immunoprecipitated ephrinB2 proteins from the cell lysis buffer with a goat polyclonal antibody, and the precipitate was assayed for coimmunoprecipitated PDZ-domain proteins by immunoblotting. Finally, to find out whether the EphB4-ephrinB2 reverse signaling affects the expression level of potential PDZ-domain proteins, preclustered soluble EphB4-Fc or Fc fragments were added to the RANKL-induced osteoclastogenic cultures. After four days in the conditioning culture, the expressions of the potential PDZ-domain proteins were assessed by the western blot and quantitative real-time RT-PCR.
Results:
The immunofluorescence staining and western blot analysis revealed that the eight PDZ-domain proteins were all expressed in the RANKL+ group after four days in the conditioning culture. However, among the eight proteins, only Dv12 showed the expected size coprecipitated with ephrinB2, and the reverse experiment (immunoprecipitation by the Dv12 antibody and immunoblotting by the ephrinB2 antibody) confirmed the relationship. The other PDZ-domain proteins were not detected at the expected sizes in the precipitate after immunoprecipitation with the ephrinB2 antibody in three independent experiments. After four days in the conditioning culture, the western blot showed that the band for Dv12 in the EphB4-Fc treated group was weaker than that in the Fc treated group (P<0.01), and the mRNA level of Dvl2 in the EphB4-Fc treated group was a little lower than in the Fc treated group, albeit with no statistical significance (P>0.05). What is more, we studied the effects of reverse signaling on the expression levels of Pickl and syntenin, PDZ-domain proteins which could not coprecipitate with ephrinB2. The western blot and quantitative real-time RT-PCR results showed that, in contrast to the similar expression level of syntenin between EphB4-Fc treated group and Fc treated group (P>0.05), the protein and mRNA expression levels of Pickl were obviously enhanced in EphB4-Fc treated group compared with Fc treated group (P<0.01).
Conclusions:
Dv12 may be the potential downstream PDZ-domain protein that is the binding partner for the C-terminal YKV motif of ephrinB2.
引文
[1]Manolagas S C. Birth and death of bone cells:basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine reviews,2000,21(2):115-137
[2]Mundy G R, Elefteriou F. Boning up on ephrin signaling. Cell.2006,126(3): 441-443
[3]Martin T J, Sims N A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends in molecular medicine,2005,11(2):76-81
[4]Phan T C, Xu J, Zheng M H. Interaction between osteoblast and osteoclast: impact in bone disease. Histology and histopathology,2004,19(4):1325-1344
[5]Teitelbaum S L, Ross F P. Genetic regulation of osteoclast development and function. Nature reviews,2003,4(8):638-649
[6]Matsuo K, Irie N. Osteoclast-osteoblast communication. Archives of biochemistry and biophysics,2008,473(2):201-209
[7]Wakeyama H, Akiyama T, Takahashi K, et al. Negative feedback loop in the Bim-caspase-3 axis regulating apoptosis and activity of osteoclasts. J Bone Miner Res,2007,22(10):1631-1639
[8]Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell,2007, 130(5):811-823
[9]Teitelbaum S L. Bone resorption by osteoclasts. Science (New York, N.Y.2000, 289(5484):1504-1508
[10]Edwards C M, Mundy G R. Eph receptors and ephrin signaling pathways:a role in bone homeostasis. International journal of medical sciences,2008,5(5): 263-272
[11]Ryu J. Kim H J, Chang E J, et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. The EMBO journal, 2006,25(24):5840-5851
[12]O'Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res,2007, 22(11):1679-1689
[13]Anderson D M, Maraskovsky E, Billingsley W L, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997,390(6656):175-179
[14]Lacey D L, Timms E, Tan H L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell,1998,93(2):165-176
[15]Wong B R, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. The Journal of biological chemistry,1997,272(40):25190-25194
[16]Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America,1998,95(7):3597-3602
[17]Hofbauer L C, Heufelder A E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. Journal of molecular medicine (Berlin, Germany),2001,79(5-6):243-253
[18]Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology,1998,139(3):1329-1337
[19]Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and biophysical research communications,1997,234(1):137-142
[20]Simonet W S, Lacey D L. Dunstan C R, et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell,1997,89(2):309-319
[21]Lam J, Takeshita S, Barker J E, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. The Journal of clinical investigation,2000,106(12):1481-1488
[22]Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends in cell biology,2007,17(5):230-238
[23]Pasquale E B. Eph-ephrin bidirectional signaling in physiology and disease. Cell, 2008,133(1):38-52
[24]Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell metabolism.2006,4(2):111-121
[25]Allan E H, Hausler K D, Wei T. et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res, 2008,23(8):1170-1181
[26]Craven S E, Bredt D S. PDZ proteins organize synaptic signaling pathways. Cell, 1998,93(4):495-498
[27]Makinen T, Adams R H, Bailey J, et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes & Development, 2005,19(3):397-410
[28]Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol,2002,3(7):475-486
[29]Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov, 2002,1(10):784-796
[30]Hofbauer L C, Khosla S, Dunstan C R, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res,2000,15(1):2-12
[31]Lomaga M A, Yeh W C, Sarosi Ⅰ, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev, 1999,13(8):1015-1024
[32]Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends in molecular medicine,2006,12(1): 17-25
[33]Leibbrandt A, Penninger J M. RANK/RANKL:regulators of immune responses and bone physiology. Annals of the New York Academy of Sciences,2008, 1143(123-150
[34]Wang L. Zheng G G. Progress in the reverse signal transduction mediated by Eph-ephrin. Progress in Biochemistry and Biophysics,2007,34(11):1142-1146
[35]Himanen J P. Nikolov D B. Eph receptors and ephrins. The international journal of biochemistry & cell biology.2003,35(2):130-134
[36]Himanen J P, Chumley M J, Lackmann M, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nature neuroscience, 2004,7(5):501-509
[37]Pasquale E B. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol,2005,6(6):462-475
[38]Hsu H, Lacey D L, Dunstan C R, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America,1999,96(7):3540-3545
[39]Ishida N, Hayashi K, Hoshijima M, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. The Journal of biological chemistry,2002,277(43):41147-41156
[40]Chambers T J, Owens J M, Hattersley G, et al. Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America,1993,90(12):5578-5582
[41]Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res,2000,15(8):1477-1488
[42]Cifuentes M, Fuentes C, Mattar P, et al. Obesity-associated proinflammatory cytokines increase calcium sensing receptor (CaSR) protein expression in primary human adipocytes and LS14 human adipose cell line. Archives of biochemistry and biophysics,2010,500(2):151-156
[43]Sanchez-Fernandez M A, Gallois A, Riedl T, et al. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PloS one,2008,3(10): e3537
[44]Gaasch J A, Bolwahnn A B, Lindsey J S. Hepatocyte growth factor-regulated genes in differentiated RAW 264.7 osteoclast and undifferentiated cells. Gene, 2006,369(142-152
[45]Raskin C A. Apoptosis and cutaneous biology. Journal of the American Academy of Dermatology,1997,36(6 Pt 1):885-896; quiz 897-888
[46]Gardner C R. Morphological analysis of osteoclastogenesis induced by RANKL in mouse bone marrow cell cultures. Cell biology international,2007,31(7): 672-682
[47]Gale N W, Yancopoulos G D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases:VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev,1999,13(9):1055-1066
[48]Myshkin E, Wang B. Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach. Journal of chemical information and computer sciences,2003,43(3):1004-1010
[49]Rahman M M, Kukita A, Kukita T, et al. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood,2003,101(9):3451-3459
[50]Faccio R, Teitelbaum S L, Fujikawa K, et al. Vav3 regulates osteoclast function and bone mass. Nature medicine,2005,11(3):284-290
[51]Arvanitis D, Davy A. Eph/ephrin signaling:networks. Genes & Development, 2008,22(4):416-429
[52]Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental cell,2002,3(6):889-901
[53]Wada T, Penninger J M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene,2004,23(16):2838-2849
[54]Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature,2001, 410(6824):37-40
[55]David J P, Sabapathy K, Hoffmann O, et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. Journal of cell science,2002,115(Pt 22):4317-4325
[56]Kenner L, Hoebertz A, Beil T, et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. The Journal of cell biology, 2004,164(4):613-623
[57]Wagner E F. Functions of API (Fos/Jun) in bone development. Annals of the rheumatic diseases,2002,61 Supp12(ii40-42
[58]Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATcl expression determines its essential role in bone homeostasis. The Journal of experimental medicine,2005,202(9):1261-1269
[59]Ikeda F, Nishimura R, Matsubara T, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. The Journal of clinical investigation,2004,114(4):475-484
[60]Matsuo K, Galson D L, Zhao C, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. The Journal of biological chemistry,2004,279(25):26475-26480
[61]Rahman M M. Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. Journal of lipid research,2006,47(8):1739-1748
[62]Bartley T D, Hunt R W, Welcher A A, et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature,1994,368(6471):558-560
[63]Beckmann M P, Cerretti D P, Baum P, et al. Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. The EMBO journal, 1994,13(16):3757-3762
[64]Cheng H J, Flanagan J G. Identification and cloning of ELF-1, a developmentally expressed ligand for the Mek4 and Sek receptor tyrosine kinases. Cell,1994,79(1):157-168
[65]Palmer A, Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes & development,2003,17(12):1429-1450
[66]Songyang Z, Fanning A S, Fu C, et al. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science (New York, N.Y,1997,275(5296): 73-77
[67]Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Annual review of neuroscience,2001,24(1-29
[68]Grembecka J, Cierpicki T, Devedjiev Y, et al. The binding of the PDZ tandem of syntenin to target proteins. Biochemistry,2006,45(11):3674-3683
[69]Brenman J E, Chao D S, Gee S H, et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alphal-syntrophin mediated by PDZ domains. Cell,1996,84(5):757-767
[70]Xu J, Xia J. Structure and function of PICK1. Neuro-Signals,2006,15(4): 190-201
[71]Torres R, Firestein B L, Dong H, et al. PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron, 1998,21(6):1453-1463
[72]Bruckner K, Pablo Labrador J, Scheiffele P, et al. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron,1999, 22(3):511-524
[73]Lin D, Gish G D, Songyang Z, et al. The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif.The Journal of biological chemistry, 1999,274(6):3726-3733
[74]Zhao J, Mao Y J, Gu Z Y. Progress in Researches of Eph/ephrin Signaling in Coupling of Bone Resorption and Bone Formation. Progress in Biochemistry and Biophysics,2009,36(9):1101-1105
[75]Lee H S, Bong Y S, Moore K B, et al. Dishevelled mediates ephrinB1 signalling in the eye field through the planar cell polarity pathway. Nature cell biology, 2006,8(1):55-63
[76]Lee H S, Mood K, Battu G, et al. Fibroblast growth factor receptor-induced phosphorylation of ephrinBl modulates its interaction with Dishevelled. Molecular biology of the cell.2009,20(1):124-133
[77][77] Tanaka M, Kamo T, Ota S, et al. Association of Dishevelled with Eph tyrosine kinase receptor and ephrin mediates cell repulsion. The EMBO journal, 2003,22(4):847-858
[78]Davy A, Soriano P. Ephrin-B2 forward signaling regulates somite patterning and neural crest cell development. Developmental biology,2007,304(1):182-193
[79]Ciani L, Salinas P C. c-Jun N-terminal kinase (JNK) cooperates with Gsk3beta to regulate Dishevelled-mediated microtubule stability. BMC cell biology,2007, 8(27
[80]Wechezak A R, Coan D E. Dv12 silencing in postdevelopmental cells results in aberrant cell membrane activity and actin disorganization. Journal of cellular physiology,2005,202(3):867-873
[81]Wallingford J B. Habas R. The developmental biology of Dishevelled:an enigmatic protein governing cell fate and cell polarity. Development (Cambridge, England),2005,132(20):4421-4436
[82]Grootjans J J, Reekmans G, Ceulemans H, et al. Syntenin-syndecan binding requires syndecan-synteny and the co-operation of both PDZ domains of syntenin. The Journal of biological chemistry,2000,275(26):19933-19941
[83]McClelland A C, Sheffler-Collins S I, Kayser M S, et al. Ephrin-B1 and ephrin-B2 mediate EphB-dependent presynaptic development via syntenin-1. Proceedings of the National Academy of Sciences of the United States of America.2009,106(48):20487-20492
[84]Dev K K. PDZ domain protein-protein interactions:a case study with PICK1. Current topics in medicinal chemistry,2007,7(1):3-20
[1]Matsuo K.Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys,2008,473(2):201-209
[2]Wakeyama H,Akiyama T,Takahashi K, et al. Negative feedback loop in the Bim-caspase-3 axis regulating apoptosis and activity of osteoclasts. J Bone Miner Res,2007,22(10):1631-1639
[3]Nakamura T.Imai Y,Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell,2007,130(5): 811-823
[4]Mundy GR,Elefteriou F. Boning up on ephrin signaling. Cell,2006,126 (3): 441-443.
[5]Edwards CM,Mundy GR. Eph Receptors and Ephrin Signaling Pathways:A Role in Bone Homeostasis. Int J Med Sci,2008,5(5):263-272
[6]Ryu J, Kim HJ, Chang EJ, et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J.2006,25 (24):5840-5851
[7]Sullivan SO, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res,2007,22 (11):1679-1689
[8]Zhao C,Irie N,Takada Y, et al.Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.Cell Metab,2006,4(2):111-121
[9]王林,郑国光Eph-ephrin介导反向信号传递的研究进展.生物化学与生物物理进展,2007,34(11)：1142-1146Wang L.Zheng GGProgress in the Reverse Signal Transduction Mediated by Eph-ephrin. Prog Biochem Biophys,2007,34(11):1142-1146
[10]Pasquale,EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol,2005,6(6):462-475
[11]Christtopher J. Vearing and Martin Jackmann. Eph receptor signaling; dimerisation just isn't enough. Growth Factors,2005,23(1):67-76
[12]Arvanitis D,Davy A.Eph/ephrin signaling:networks. Genes Dev,2008,22(4):416-429
[13]Egea J,Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol,2007,17(5):230-238
[14]Poliakov A,Cotrina M and Wilkinson DG. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell,2004,7(4):465-4801
[15]Allan EH,Hausler KD,Wei T, et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res.2008,23(8):1170-1181
[16]Lorenzo J. Ephs and ephrins:a new way for bone cells to communicate. J Bone Miner Res,2008.23(8):1168-1169
[17]Kuroda C, Kubota S, Kawata K. et al.Distribution, gene expression, and functional role of EphA4 during ossification. Biochem Biophys Res Commun,2008,374 (1): 22-27
[18]Wang Y,Nishida S,Boudignon BM, et al. IGF-Ⅰ receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res, 2007,22(9):1329-1337
[19]Noren NK,Pasquale EB.Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal,2004,16(6),655-666
[20]Harmey D, Stenbeck G, Nobe CD, et al. Regulation of osteoblast differentiation by Pasteurella multocida toxin (PMT):a role for Rho GTPase in bone formation. J Bone Miner Res,2004,19(4):661-670
[21]Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell.2008,133(1):38-52
[22]Compagni A,Xogan M.Klein R, et al. Control of skeletal patterning by ephrinbl-ephb interactions. Dev Cel,2003,5(2):217-230
[23]Davy A,Bush JO,Soriano P. Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. PloS Biol,2006, 4(10):1763-1776
[24]Davy A,Aubin J,Soriano P. Ephrin-bl forward and reverse signaling are required during mouse development. Genes Dev,2004,18(5):572-583
[25]Twigg SR,Kan R,Babbs C, et al. Mutations of ephrin-B1 (EFNB1), a marker of tissue bundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci USA.2004,101(23):8652-8657
[26]Wieland I,Jakubiczka S.Muschke P, et al. Mutations of the ephrin-bl gene cause craniofrontonasal syndrome. Am J Hum Genet,2004,74(6):1209-1215
[27]Bates AL, Mundy GR,Edwards CM. Myeloma cells decrease EphB4 expression in steoblasts:A novel mechanism for regulation of bone formation in multiple myeloma. Cancer Treatment Reviews,2008,34(Suppl 1):S63
[28]Kwan Tat S, Pelletier JP, Amiable N, et al. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Arthritis Rheum,2008,58(12):3820-3830
[29]Vaught D, Brantley-Sieders DM,Chen J. Epha2 induced osteolysis:A novel mechanism for osteoclast activation mediated by breast cancer-bone cell interactions. Proceedings of the 9th Annual Meeting of the American Association for Cancer Research.2008:2523
[30]Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone,liver and lymph node metastases. Clin Exp Metastasis.2008,25(4):377-388
[2]Mundy G R, Elefteriou F. Boning up on ephrin signaling. Cell.2006,126(3): 441-443
[3]Martin T J, Sims N A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends in molecular medicine,2005,11(2):76-81
[4]Phan T C, Xu J, Zheng M H. Interaction between osteoblast and osteoclast: impact in bone disease. Histology and histopathology,2004,19(4):1325-1344
[5]Teitelbaum S L, Ross F P. Genetic regulation of osteoclast development and function. Nature reviews,2003,4(8):638-649
[6]Matsuo K, Irie N. Osteoclast-osteoblast communication. Archives of biochemistry and biophysics,2008,473(2):201-209
[7]Wakeyama H, Akiyama T, Takahashi K, et al. Negative feedback loop in the Bim-caspase-3 axis regulating apoptosis and activity of osteoclasts. J Bone Miner Res,2007,22(10):1631-1639
[8]Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell,2007, 130(5):811-823
[9]Teitelbaum S L. Bone resorption by osteoclasts. Science (New York, N.Y.2000, 289(5484):1504-1508
[10]Edwards C M, Mundy G R. Eph receptors and ephrin signaling pathways:a role in bone homeostasis. International journal of medical sciences,2008,5(5): 263-272
[11]Ryu J. Kim H J, Chang E J, et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. The EMBO journal, 2006,25(24):5840-5851
[12]O'Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res,2007, 22(11):1679-1689
[13]Anderson D M, Maraskovsky E, Billingsley W L, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997,390(6656):175-179
[14]Lacey D L, Timms E, Tan H L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell,1998,93(2):165-176
[15]Wong B R, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. The Journal of biological chemistry,1997,272(40):25190-25194
[16]Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America,1998,95(7):3597-3602
[17]Hofbauer L C, Heufelder A E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. Journal of molecular medicine (Berlin, Germany),2001,79(5-6):243-253
[18]Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology,1998,139(3):1329-1337
[19]Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and biophysical research communications,1997,234(1):137-142
[20]Simonet W S, Lacey D L. Dunstan C R, et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell,1997,89(2):309-319
[21]Lam J, Takeshita S, Barker J E, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. The Journal of clinical investigation,2000,106(12):1481-1488
[22]Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends in cell biology,2007,17(5):230-238
[23]Pasquale E B. Eph-ephrin bidirectional signaling in physiology and disease. Cell, 2008,133(1):38-52
[24]Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell metabolism.2006,4(2):111-121
[25]Allan E H, Hausler K D, Wei T. et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res, 2008,23(8):1170-1181
[26]Craven S E, Bredt D S. PDZ proteins organize synaptic signaling pathways. Cell, 1998,93(4):495-498
[27]Makinen T, Adams R H, Bailey J, et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes & Development, 2005,19(3):397-410
[28]Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol,2002,3(7):475-486
[29]Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov, 2002,1(10):784-796
[30]Hofbauer L C, Khosla S, Dunstan C R, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res,2000,15(1):2-12
[31]Lomaga M A, Yeh W C, Sarosi Ⅰ, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev, 1999,13(8):1015-1024
[32]Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends in molecular medicine,2006,12(1): 17-25
[33]Leibbrandt A, Penninger J M. RANK/RANKL:regulators of immune responses and bone physiology. Annals of the New York Academy of Sciences,2008, 1143(123-150
[34]Wang L. Zheng G G. Progress in the reverse signal transduction mediated by Eph-ephrin. Progress in Biochemistry and Biophysics,2007,34(11):1142-1146
[35]Himanen J P. Nikolov D B. Eph receptors and ephrins. The international journal of biochemistry & cell biology.2003,35(2):130-134
[36]Himanen J P, Chumley M J, Lackmann M, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nature neuroscience, 2004,7(5):501-509
[37]Pasquale E B. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol,2005,6(6):462-475
[38]Hsu H, Lacey D L, Dunstan C R, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America,1999,96(7):3540-3545
[39]Ishida N, Hayashi K, Hoshijima M, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. The Journal of biological chemistry,2002,277(43):41147-41156
[40]Chambers T J, Owens J M, Hattersley G, et al. Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America,1993,90(12):5578-5582
[41]Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res,2000,15(8):1477-1488
[42]Cifuentes M, Fuentes C, Mattar P, et al. Obesity-associated proinflammatory cytokines increase calcium sensing receptor (CaSR) protein expression in primary human adipocytes and LS14 human adipose cell line. Archives of biochemistry and biophysics,2010,500(2):151-156
[43]Sanchez-Fernandez M A, Gallois A, Riedl T, et al. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PloS one,2008,3(10): e3537
[44]Gaasch J A, Bolwahnn A B, Lindsey J S. Hepatocyte growth factor-regulated genes in differentiated RAW 264.7 osteoclast and undifferentiated cells. Gene, 2006,369(142-152
[45]Raskin C A. Apoptosis and cutaneous biology. Journal of the American Academy of Dermatology,1997,36(6 Pt 1):885-896; quiz 897-888
[46]Gardner C R. Morphological analysis of osteoclastogenesis induced by RANKL in mouse bone marrow cell cultures. Cell biology international,2007,31(7): 672-682
[47]Gale N W, Yancopoulos G D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases:VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev,1999,13(9):1055-1066
[48]Myshkin E, Wang B. Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach. Journal of chemical information and computer sciences,2003,43(3):1004-1010
[49]Rahman M M, Kukita A, Kukita T, et al. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood,2003,101(9):3451-3459
[50]Faccio R, Teitelbaum S L, Fujikawa K, et al. Vav3 regulates osteoclast function and bone mass. Nature medicine,2005,11(3):284-290
[51]Arvanitis D, Davy A. Eph/ephrin signaling:networks. Genes & Development, 2008,22(4):416-429
[52]Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental cell,2002,3(6):889-901
[53]Wada T, Penninger J M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene,2004,23(16):2838-2849
[54]Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature,2001, 410(6824):37-40
[55]David J P, Sabapathy K, Hoffmann O, et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. Journal of cell science,2002,115(Pt 22):4317-4325
[56]Kenner L, Hoebertz A, Beil T, et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. The Journal of cell biology, 2004,164(4):613-623
[57]Wagner E F. Functions of API (Fos/Jun) in bone development. Annals of the rheumatic diseases,2002,61 Supp12(ii40-42
[58]Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATcl expression determines its essential role in bone homeostasis. The Journal of experimental medicine,2005,202(9):1261-1269
[59]Ikeda F, Nishimura R, Matsubara T, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. The Journal of clinical investigation,2004,114(4):475-484
[60]Matsuo K, Galson D L, Zhao C, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. The Journal of biological chemistry,2004,279(25):26475-26480
[61]Rahman M M. Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. Journal of lipid research,2006,47(8):1739-1748
[62]Bartley T D, Hunt R W, Welcher A A, et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature,1994,368(6471):558-560
[63]Beckmann M P, Cerretti D P, Baum P, et al. Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. The EMBO journal, 1994,13(16):3757-3762
[64]Cheng H J, Flanagan J G. Identification and cloning of ELF-1, a developmentally expressed ligand for the Mek4 and Sek receptor tyrosine kinases. Cell,1994,79(1):157-168
[65]Palmer A, Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes & development,2003,17(12):1429-1450
[66]Songyang Z, Fanning A S, Fu C, et al. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science (New York, N.Y,1997,275(5296): 73-77
[67]Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Annual review of neuroscience,2001,24(1-29
[68]Grembecka J, Cierpicki T, Devedjiev Y, et al. The binding of the PDZ tandem of syntenin to target proteins. Biochemistry,2006,45(11):3674-3683
[69]Brenman J E, Chao D S, Gee S H, et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alphal-syntrophin mediated by PDZ domains. Cell,1996,84(5):757-767
[70]Xu J, Xia J. Structure and function of PICK1. Neuro-Signals,2006,15(4): 190-201
[71]Torres R, Firestein B L, Dong H, et al. PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron, 1998,21(6):1453-1463
[72]Bruckner K, Pablo Labrador J, Scheiffele P, et al. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron,1999, 22(3):511-524
[73]Lin D, Gish G D, Songyang Z, et al. The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif.The Journal of biological chemistry, 1999,274(6):3726-3733
[74]Zhao J, Mao Y J, Gu Z Y. Progress in Researches of Eph/ephrin Signaling in Coupling of Bone Resorption and Bone Formation. Progress in Biochemistry and Biophysics,2009,36(9):1101-1105
[75]Lee H S, Bong Y S, Moore K B, et al. Dishevelled mediates ephrinB1 signalling in the eye field through the planar cell polarity pathway. Nature cell biology, 2006,8(1):55-63
[76]Lee H S, Mood K, Battu G, et al. Fibroblast growth factor receptor-induced phosphorylation of ephrinBl modulates its interaction with Dishevelled. Molecular biology of the cell.2009,20(1):124-133
[77][77] Tanaka M, Kamo T, Ota S, et al. Association of Dishevelled with Eph tyrosine kinase receptor and ephrin mediates cell repulsion. The EMBO journal, 2003,22(4):847-858
[78]Davy A, Soriano P. Ephrin-B2 forward signaling regulates somite patterning and neural crest cell development. Developmental biology,2007,304(1):182-193
[79]Ciani L, Salinas P C. c-Jun N-terminal kinase (JNK) cooperates with Gsk3beta to regulate Dishevelled-mediated microtubule stability. BMC cell biology,2007, 8(27
[80]Wechezak A R, Coan D E. Dv12 silencing in postdevelopmental cells results in aberrant cell membrane activity and actin disorganization. Journal of cellular physiology,2005,202(3):867-873
[81]Wallingford J B. Habas R. The developmental biology of Dishevelled:an enigmatic protein governing cell fate and cell polarity. Development (Cambridge, England),2005,132(20):4421-4436
[82]Grootjans J J, Reekmans G, Ceulemans H, et al. Syntenin-syndecan binding requires syndecan-synteny and the co-operation of both PDZ domains of syntenin. The Journal of biological chemistry,2000,275(26):19933-19941
[83]McClelland A C, Sheffler-Collins S I, Kayser M S, et al. Ephrin-B1 and ephrin-B2 mediate EphB-dependent presynaptic development via syntenin-1. Proceedings of the National Academy of Sciences of the United States of America.2009,106(48):20487-20492
[84]Dev K K. PDZ domain protein-protein interactions:a case study with PICK1. Current topics in medicinal chemistry,2007,7(1):3-20
[1]Matsuo K.Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys,2008,473(2):201-209
[2]Wakeyama H,Akiyama T,Takahashi K, et al. Negative feedback loop in the Bim-caspase-3 axis regulating apoptosis and activity of osteoclasts. J Bone Miner Res,2007,22(10):1631-1639
[3]Nakamura T.Imai Y,Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell,2007,130(5): 811-823
[4]Mundy GR,Elefteriou F. Boning up on ephrin signaling. Cell,2006,126 (3): 441-443.
[5]Edwards CM,Mundy GR. Eph Receptors and Ephrin Signaling Pathways:A Role in Bone Homeostasis. Int J Med Sci,2008,5(5):263-272
[6]Ryu J, Kim HJ, Chang EJ, et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J.2006,25 (24):5840-5851
[7]Sullivan SO, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res,2007,22 (11):1679-1689
[8]Zhao C,Irie N,Takada Y, et al.Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.Cell Metab,2006,4(2):111-121
[9]王林,郑国光Eph-ephrin介导反向信号传递的研究进展.生物化学与生物物理进展,2007,34(11)：1142-1146Wang L.Zheng GGProgress in the Reverse Signal Transduction Mediated by Eph-ephrin. Prog Biochem Biophys,2007,34(11):1142-1146
[10]Pasquale,EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol,2005,6(6):462-475
[11]Christtopher J. Vearing and Martin Jackmann. Eph receptor signaling; dimerisation just isn't enough. Growth Factors,2005,23(1):67-76
[12]Arvanitis D,Davy A.Eph/ephrin signaling:networks. Genes Dev,2008,22(4):416-429
[13]Egea J,Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol,2007,17(5):230-238
[14]Poliakov A,Cotrina M and Wilkinson DG. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell,2004,7(4):465-4801
[15]Allan EH,Hausler KD,Wei T, et al. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res.2008,23(8):1170-1181
[16]Lorenzo J. Ephs and ephrins:a new way for bone cells to communicate. J Bone Miner Res,2008.23(8):1168-1169
[17]Kuroda C, Kubota S, Kawata K. et al.Distribution, gene expression, and functional role of EphA4 during ossification. Biochem Biophys Res Commun,2008,374 (1): 22-27
[18]Wang Y,Nishida S,Boudignon BM, et al. IGF-Ⅰ receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res, 2007,22(9):1329-1337
[19]Noren NK,Pasquale EB.Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal,2004,16(6),655-666
[20]Harmey D, Stenbeck G, Nobe CD, et al. Regulation of osteoblast differentiation by Pasteurella multocida toxin (PMT):a role for Rho GTPase in bone formation. J Bone Miner Res,2004,19(4):661-670
[21]Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell.2008,133(1):38-52
[22]Compagni A,Xogan M.Klein R, et al. Control of skeletal patterning by ephrinbl-ephb interactions. Dev Cel,2003,5(2):217-230
[23]Davy A,Bush JO,Soriano P. Inhibition of gap junction communication at ectopic Eph/ephrin boundaries underlies craniofrontonasal syndrome. PloS Biol,2006, 4(10):1763-1776
[24]Davy A,Aubin J,Soriano P. Ephrin-bl forward and reverse signaling are required during mouse development. Genes Dev,2004,18(5):572-583
[25]Twigg SR,Kan R,Babbs C, et al. Mutations of ephrin-B1 (EFNB1), a marker of tissue bundary formation, cause craniofrontonasal syndrome. Proc Natl Acad Sci USA.2004,101(23):8652-8657
[26]Wieland I,Jakubiczka S.Muschke P, et al. Mutations of the ephrin-bl gene cause craniofrontonasal syndrome. Am J Hum Genet,2004,74(6):1209-1215
[27]Bates AL, Mundy GR,Edwards CM. Myeloma cells decrease EphB4 expression in steoblasts:A novel mechanism for regulation of bone formation in multiple myeloma. Cancer Treatment Reviews,2008,34(Suppl 1):S63
[28]Kwan Tat S, Pelletier JP, Amiable N, et al. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Arthritis Rheum,2008,58(12):3820-3830
[29]Vaught D, Brantley-Sieders DM,Chen J. Epha2 induced osteolysis:A novel mechanism for osteoclast activation mediated by breast cancer-bone cell interactions. Proceedings of the 9th Annual Meeting of the American Association for Cancer Research.2008:2523
[30]Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone,liver and lymph node metastases. Clin Exp Metastasis.2008,25(4):377-388